By contrast, transgenic mice with parts of the GluN2B C-terminal domain (CTD) region deleted or modified experienced decreased susceptibility to in vitro NMDA-induced cell death and an in vivo middle cerebral artery occlusion (MCAO) model of stroke (Martel et al., 2012; Vieira et al., 2016; Tang et al., 2018). The gene discussed is GRIN2B; the disease is stroke disorder.